
    
      This is a Phase 1-3, multi-center, double-blind, placebo-controlled, multiple-ascending dose
      (MAD) study in up to 58 patients with AxD. Participants will be randomized in a 2:1 ratio to
      receive ION373 or matching placebo for a 60-week double-blind treatment period; then all
      participants will receive ION373 for a 60-week open-label treatment period.
    
  